These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 18489949)

  • 1. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension.
    Chin KM; Kingman M; de Lemos JA; Warner JJ; Reimold S; Peshock R; Torres F
    Am J Cardiol; 2008 Jun; 101(11):1669-72. PubMed ID: 18489949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.
    van de Veerdonk MC; Kind T; Marcus JT; Mauritz GJ; Heymans MW; Bogaard HJ; Boonstra A; Marques KM; Westerhof N; Vonk-Noordegraaf A
    J Am Coll Cardiol; 2011 Dec; 58(24):2511-9. PubMed ID: 22133851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: determinants and impact on pump function.
    Badagliacca R; Poscia R; Pezzuto B; Papa S; Gambardella C; Francone M; Mezzapesa M; Nocioni M; Nona A; Rosati R; Sciomer S; Fedele F; Dario Vizza C
    J Heart Lung Transplant; 2015 Mar; 34(3):381-9. PubMed ID: 25087105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apical right ventricular dysfunction in patients with pulmonary hypertension demonstrated with magnetic resonance.
    Fernandez-Friera L; Garcia-Alvarez A; Guzman G; Bagheriannejad-Esfahani F; Malick W; Nair A; Fuster V; Garcia MJ; Sanz J
    Heart; 2011 Aug; 97(15):1250-6. PubMed ID: 21672942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
    Surie S; Reesink HJ; Marcus JT; van der Plas MN; Kloek JJ; Vonk-Noordegraaf A; Bresser P
    Clin Cardiol; 2013 Nov; 36(11):698-703. PubMed ID: 24037998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RV dysfunction in pulmonary hypertension is independently related to pulmonary artery stiffness.
    Stevens GR; Garcia-Alvarez A; Sahni S; Garcia MJ; Fuster V; Sanz J
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):378-87. PubMed ID: 22498327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension.
    van de Veerdonk MC; Marcus JT; Westerhof N; de Man FS; Boonstra A; Heymans MW; Bogaard HJ; Vonk Noordegraaf A
    Chest; 2015 Apr; 147(4):1063-1071. PubMed ID: 25376008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients.
    Gan CT; Holverda S; Marcus JT; Paulus WJ; Marques KM; Bronzwaer JG; Twisk JW; Boonstra A; Postmus PE; Vonk-Noordegraaf A
    Chest; 2007 Jul; 132(1):11-7. PubMed ID: 17625080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-diastolic left ventricular lengthening implies pulmonary hypertension-induced right ventricular decompensation.
    Lumens J; Arts T; Marcus JT; Vonk-Noordegraaf A; Delhaas T
    Cardiovasc Res; 2012 Nov; 96(2):286-95. PubMed ID: 22875469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and metabolic recovery of the right ventricle during Bosentan therapy in idiopathic pulmonary arterial hypertension.
    Spindler M; Schmidt M; Geier O; Sandstede J; Hahn D; Ertl G; Beer M
    J Cardiovasc Magn Reson; 2005; 7(5):853-4. PubMed ID: 16353449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed improvement of right ventricular diastolic function and regression of right ventricular mass after percutaneous pulmonary valve implantation in patients with congenital heart disease.
    Romeih S; Kroft LJ; Bokenkamp R; Schalij MJ; Grotenhuis H; Hazekamp MG; Groenink M; de Roos A; Blom NA
    Am Heart J; 2009 Jul; 158(1):40-6. PubMed ID: 19540390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
    Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study.
    Kim H; Bae Lee J; Park JH; Yoo BS; Son JW; Yang DH; Lee BR
    J Clin Ultrasound; 2017 Jan; 45(1):28-34. PubMed ID: 27619758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension.
    van Wolferen SA; Marcus JT; Boonstra A; Marques KM; Bronzwaer JG; Spreeuwenberg MD; Postmus PE; Vonk-Noordegraaf A
    Eur Heart J; 2007 May; 28(10):1250-7. PubMed ID: 17242010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome.
    Kaya MG; Lam YY; Erer B; Ayhan S; Vatankulu MA; Nurkalem Z; Meric M; Eren M; Eryol NK
    J Card Fail; 2012 May; 18(5):379-84. PubMed ID: 22555267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension.
    So PP; Davies RA; Chandy G; Stewart D; Beanlands RS; Haddad H; Pugliese C; Mielniczuk LM
    Am J Cardiol; 2012 May; 109(10):1504-9. PubMed ID: 22385756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricuspid regurgitation duration correlates with cardiovascular magnetic resonance-derived right ventricular ejection fraction and predict prognosis in patients with pulmonary arterial hypertension.
    Cho IJ; Oh J; Chang HJ; Park J; Kang KW; Kim YJ; Choi BW; Shin S; Shim CY; Hong GR; Ha JW; Chung N
    Eur Heart J Cardiovasc Imaging; 2014 Jan; 15(1):18-23. PubMed ID: 23704751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.